Drugs / LingZhi
LingZhi
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06028022 | Oct 2023 → Aug 2027 expected | estrogen-receptor positive breast cancer | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT00224263 | Sep 2005 → Feb 2008 | Parkinson disease | Xuanwu Hospital, Beijing | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06601283 | Nov 2024 → Nov 2026 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06598033 | Nov 2024 → Oct 2026 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03594656 | Jul 2018 → Dec 2021 | Parkinson disease | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT02486796 Comparator | Feb 2016 → Mar 2017 | — | Midwestern Regional Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00575926 Comparator | Sep 2002 → Sep 2007 | childhood malignant neoplasm | Chinese University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LingZhi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00575926 ↗ |
| Known as | Ganoderma | “Lingzhi (Ganoderma)” NCT00224263 ↗ |
| Known as | Reishi | “numerous evidence has proved the efficacy of Reishi and Cordyceps in alleviating the side effects related to chemotherapy.” NCT06598033 ↗1“Reishi, 2 g/day, BID, PO.” NCT06601283 ↗ |
| Known as | Reishi mushroom extract | “Given Reishi mushroom extract PO” NCT06028022 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Lingzhi (Ganoderma), a widely used traditional Chinese Medicine” NCT00224263 ↗ |
| Route | Oral | “Oral 300mg capsules containing Lingzhi extract” NCT00575926 ↗ |